As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of ...

A father from Seattle, Washington was shocked and overwhelmed after strangers came together to raise more than $150k for him to go through life-saving cancer treatment.

Despite new paradigm-shifting treatments, lung cancer remains a deadly ... as the percentage of patients whose cancer cells die by more than 90% in the resected specimen, however the definition ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

Human health is strongly intertwined with the health of the microbiome. A large number of studies have shown that the human ...

The discovery is of great interest for cancer medicine because a change of ... Lung Cancer Cells Can Go 'Off Grid' Feb. 12, 2025 — Researchers have found that some particularly aggressive lung ...

The following is a summary of "Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...